// App-Quantinova.ai

306 : Efficacy of Obeticholic Acid Treatment Through 24 Months of Open‐Label Extension in Patients with Primary Biliary Cholangitis and Cirrhosis: Data From POISE

Researchers

Presenter

  • John M. Vierling

Principal Investigators

  • Gideon M. Hirschfield

  • David Jones

  • Roberto J. Groszmann

  • Kris V. Kowdley

  • Richard Pencek

  • Elizabeth Smoot Malecha

  • Leigh MacConell

Medical Centers

  • Baylor College of Medicine, Houston, TX

  • University of Birmingham, Birmingham, United Kingdom

  • Newcastle University, Newcastle upon Tyne, United Kingdom

  • Yale University School of Medicine, New Haven, CT

  • Swedish Medical Center, Seattle, WA

  • Polaris Pharmaceuticals Inc, San Diego, CA

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Primary biliary cirrhosis

  • Cirrhosis

Biomarkers

  • Alkaline phosphatase

Drug/Treatment

  • Alkaline phosphatase

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved